Skip to main content
Clinical Trials/CTRI/2025/09/094991
CTRI/2025/09/094991
Not yet recruiting
Not Applicable

Management of Autism spectrum disorder in children with individualized homoeopathic remedy versus individualized homoeopathic remedy with Bach flower remedy as an adjuvant :A prospective single blind clinical trial.

Dr Deepalika Sharma1 site in 1 country30 target enrollmentStarted: September 25, 2025Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Dr Deepalika Sharma
Enrollment
30
Locations
1
Primary Endpoint
Improvement in behavioral, cognitive and emotional symptoms in children with ASD, measured using the ISAA pre, mid, and post stage .

Overview

Brief Summary

A prospective, single-blind,   computerized randomized clinical trial to compare the effectiveness of individualized homoeopathic remedy alone versus individualized homoeopathic remedy with Bach Flower Remedies (BFRs) as an adjuvant in the management of Autism Spectrum Disorder (ASD) in children of  aged 5–12 years  group .

A total of 30 pre-diagnosed cases of mild to moderate ASD will be enrolled and random allocated into  two  parallel groups each group will have 15 participants :

Group A: Individualized homoeopathic remedy

Group B: Individualized homoeopathic remedy with Bach flower remedies (BFRs) as adjuvant

The intervention will be administered for 6 months, with follow-up over 6 months. Outcomes will be assessed using the Indian Scale for Assessment of Autism (ISAA) at baseline, mid-point, and post-treatment.

Primary outcome: Improvement in behavioral, cognitive, and emotional symptoms in ASD children. Secondary outcomes: Improvement in quality of life and  documentation of the effectiveness  of Bach flower remedies  BFRs as an adjuvant to individualized homoeopathic remedy .

Statistical analysis will be performed using the Independent T-test to compare differences between groups.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant Blinded

Eligibility Criteria

Ages
5.00 Year(s) to 12.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 1.Children age 5-12 years .
  • 2.Patient of both the sexes male and female 3.Mild and moderate autism according to ISAA scale 4.Parent able to provide written informed accent .

Exclusion Criteria

  • 1.Severe autism according to ISAA scale.
  • Presence of other neurological disorder.
  • 3.Participation in other clinical trials in past 3 month.
  • 4.Patient age of below 5 year and above 12 years.

Outcomes

Primary Outcomes

Improvement in behavioral, cognitive and emotional symptoms in children with ASD, measured using the ISAA pre, mid, and post stage .

Time Frame: 6 months

Secondary Outcomes

  • 1.Improvement in quality of life in children with ASD.(2.Effectiveness of Bach Flower Remedy as an adjuvant to individualized homoeopathic remedy .)

Investigators

Sponsor
Dr Deepalika Sharma
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Deepalika Sharma

BVDUHMC - PUNE

Study Sites (1)

Loading locations...

Similar Trials